Artrya Limited
2.65
AUD
0.00
(0.00%)
ISIN
AU0000182412
Return %
Stock
S&P 500
1Y
-20.66
14.20
3Y
1,294.74
81.12
5Y
- -
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- John Konstantopoulos
- Full Time Employees
- 43
- Sector
- Technology services
- Industry
- Packaged software
- Address
- 1257 Hay Street West Perth WA Australia 6005
- IPO Date
- Nov 24, 2021
- Website
- artrya.com
- Similar Companies
- Business
- Artrya Limited (ASX:AYA) is a medical technology company that develops and commercializes artificial intelligence-powered software platforms for the detection, diagnosis, and management of coronary artery disease using coronary computed tomography angiography (CCTA) imaging; its flagship Artrya Salix suite includes Salix Coronary Plaque (SCP), which automates real-time plaque feature analysis to identify high-risk lesions and enable rapid patient stratification in emergency and primary care settings, Salix Coronary Flow (SCF) for assessing coronary blood flow limitations, and Salix Coronary Anatomy for anatomical assessments; the cloud-based platform supports clinicians with non-invasive, precise diagnostic support to reduce heart attack risks, optimize workflows, facilitate evidence-based discharge decisions, and lower healthcare costs by avoiding unnecessary invasive procedures and readmissions. Founded in 2019 and headquartered at 1257 Hay Street, West Perth, Australia, Artrya targets global cardiovascular care markets, including clinics handling chest pain patients, with initial commercialization in Australia and expanding into the United States. Recent developments include FDA clearance for Salix Coronary Plaque in March 2025 enabling per-scan revenue generation of approximately US$750 in the US, its June 2025 submission of Salix Coronary Flow for FDA approval anticipated by year-end, the ongoing SAPPHIRE clinical study negotiations with 6-8 US healthcare partners representing 400,000 annual CCTA scans worth US$342 million in potential revenue, a February 2025 capital raising, a $5 million placement in 2024, and a $75 million placement in 2025 to fund US commercialization and regulatory milestones.